BBCIC is the only research consortium dedicated to evaluating the real-world safety and effectiveness of biologics, including biosimilars.
BBCIC is a non-profit research consortium that monitors the safety and effectiveness of biosimilars and novel biologics and provides the assurance needed to determine which medications deliver the best health outcomes.
AMCP established BBCIC in 2015 to address anticipated needs for post-marketed evidence generation for novel biologics, their corresponding biosimilars, and other related products.
To generate reliable real-world evidence that examines the safety and effectiveness of biologics in order to improve public health.
Leadership and Governance
BBCIC is led by Executive Director Cate Lockhart, MS, PharmD, PhD, and governed by a Board of Managing Directors, Planning Board, and Science Committee.
The BBCIC Charter details the principles and policies governing the consortium’s research projects and the latest version was approved by the BBCIC Board of Managing Directors on September 16, 2022.